专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09262076B2 Soft keyboard interface 有权
标题翻译：软键盘界面
公开(公告)号：US09262076B2
公开(公告)日：2016-02-16
申请号：US13230723
申请日：2011-09-12
申请人： Reed L. Townsend , Mudit Agrawal , Andrey Borissov Batchvarov , Fei Su
发明人： Reed L. Townsend , Mudit Agrawal , Andrey Borissov Batchvarov , Fei Su
IPC分类号： G06F3/048 , G06F3/0489 , G06F3/0488 , G06F3/0481
CPC分类号： G06F3/04895 , G06F3/0481 , G06F3/04886
摘要： User experience of the performance of a computing device is improved through an operating system that processes inputs from a soft keyboard to provide information that can be used to accurately determine keys a user intended to strike while typing. For each detected tap, the operating system provides a probability that one or more keys were the intended target for the user. These probabilities may be computed from probability distribution functions that are dynamically determined based on user and/or system factors, such as typing rate and keyboard style or layout. Other components may use the probabilities to select a key corresponding to a detected keyboard tap as representing the intended user input. The selection may be made based on the probabilities alone or in combination with contextual factors that yield an overall probability that a detected tap arose from a user targeting a specific key.
摘要翻译：通过处理来自软键盘的输入的操作系统来提高计算设备的性能的用户体验，以提供可用于准确地确定打字时用户打算敲击的键的信息。对于每个检测到的抽头，操作系统提供一个或多个键是用户的预期目标的概率。这些概率可以根据基于用户和/或系统因素动态确定的概率分布函数来计算，诸如打字率和键盘风格或布局。其他组件可以使用概率来选择与检测到的键盘抽头对应的键来表示预期的用户输入。可以基于单独的概率或与产生检测到的抽头从针对特定键的用户产生的总体概率的上下文因素组合来进行选择。

2. 发明授权

US07949035B2 GPS signal acquisition system and method 有权
标题翻译： GPS信号采集系统及方法
公开(公告)号：US07949035B2
公开(公告)日：2011-05-24
申请号：US11611162
申请日：2006-12-15
申请人： Fei Su
发明人： Fei Su
IPC分类号： H04B1/00
CPC分类号： H04B1/7083 , G01S19/24 , G01S19/37 , H04B1/7075 , H04B2201/70715
摘要： A Global Position System signal acquiring system and method is provided in this invention. Pluralities of counters are set, each corresponding to a code bin and a frequency bin of the signal. Subsequently, the signal corresponding to the counters is repeatedly received in a unit of time and the counters are accordingly updated for a pre-determined iteration. At last, a maximum value among the counters is found to acquire the signal corresponding to the counter having the maximum value.
摘要翻译：本发明提供了一种全球定位系统信号采集系统和方法。设置多个计数器，每个计数器对应于信号的码仓和频率仓。随后，以单位时间重复地接收对应于计数器的信号，并且相应地更新计数器以进行预定的迭代。最后，发现计数器中的最大值获取对应于具有最大值的计数器的信号。

3. 发明申请

US20120045433A1 COMBINATION THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：US20120045433A1
公开(公告)日：2012-02-23
申请号：US13206548
申请日：2011-08-10
申请人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
发明人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
IPC分类号： A61K31/437 , A61K39/395 , A61P35/00 , A61K31/4545
CPC分类号： A61K31/00 , A61K31/437 , A61K31/4745 , A61K39/39558 , A61K45/06 , A61K2039/545 , C07K16/2863 , A61K2300/00
摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an topoisomerase inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the topoisomerase inhibitor is irinotecan, or a pharmaceutically acceptable salt thereof, and the disorder is colorectal cancer involving a tumor comprising b-Raf having the V600E mutation.
摘要翻译：本发明涉及丙烷-1-磺酸{3- [5-（4-氯苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基] -2,4-二氟 - 苯基} - 酰胺或其药学上可接受的盐，和拓扑异构酶抑制剂，用于治疗患有增殖性病症的患者，特别是实体瘤，例如结肠直肠癌，黑素瘤和甲状腺癌。特别地，本发明涉及这样的治疗方法，其中拓扑异构酶抑制剂是伊立替康或其药学上可接受的盐，该病症是涉及包含具有V600E突变的b-Raf的肿瘤的结肠直肠癌。

4. 发明授权

US09125330B2 Pin structure and pin connection structure thereof 有权
标题翻译：引脚结构及引脚连接结构
公开(公告)号：US09125330B2
公开(公告)日：2015-09-01
申请号：US13479283
申请日：2012-05-24
申请人： Fei Su , Meifang Lan , Hao Wei , Jiantong Chen , Yufang Xiong , Yicong Su
发明人： Fei Su , Meifang Lan , Hao Wei , Jiantong Chen , Yufang Xiong , Yicong Su
IPC分类号： H01R4/58 , H05K3/32 , H05K1/11 , H05K3/36
CPC分类号： H05K3/323 , H01L2224/73204 , H05K1/11 , H05K3/361 , H05K2201/09663
摘要： The present disclosure relates to a conductive connection structure, and more particularly to a pin structure and pin connection structure thereof. The pin structure is disposed at least one side of an anisotropic conductive film. A plurality of conductive particles is distributed over the interior of the anisotropic conductive film. The pin structure comprises: a plurality of columns which are interspaced, wherein, the conductive particles are in the periphery of the columns. The pin structure and pin connection structure provided by the present disclosure use a pin structure comprising a plurality of columns which are interspaced. When the anisotropic conductive film is used to laminate pin structures, spacing between adjacent columns can contain the conductive particles so as to reduce the number of conductive particle that flow between the left-and-right adjacent pin structures, thereby reducing incidence of short circuit of the left-and-right adjacent pin structures.
摘要翻译：导体连接结构技术领域本发明涉及一种导电连接结构，更具体地说，涉及一种针脚结构和针连接结构。针结构设置在各向异性导电膜的至少一侧。多个导电粒子分布在各向异性导电膜的内部。针结构包括：多个间隔的柱，其中，导电颗粒在柱的周边。由本公开提供的销结构和销连接结构使用包括间隔的多个列的销结构。当各向异性导电膜用于层压销结构时，相邻列之间的间隔可以包含导电颗粒，以减少在左右相邻引脚结构之间流动的导电粒子的数量，从而减少左右相邻的销结构。

5. 发明授权

US08709419B2 Combination therapy 有权
标题翻译：联合治疗
公开(公告)号：US08709419B2
公开(公告)日：2014-04-29
申请号：US13206557
申请日：2011-08-10
申请人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
发明人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
IPC分类号： A61K39/00 , A61K31/517 , A61K31/44
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/437 , A61K31/517 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
摘要翻译：本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基] 二氟 - 苯基} - 酰胺或其药学上可接受的盐，以及用于治疗患有增殖性病症的患者，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的EGFR抑制剂。

6. 发明申请

US20130067382A1 SOFT KEYBOARD INTERFACE 有权
标题翻译：软键盘接口
公开(公告)号：US20130067382A1
公开(公告)日：2013-03-14
申请号：US13230723
申请日：2011-09-12
申请人： Reed L. Townsend , Mudit Agrawal , Andrey Borissov Batchvarov , Fei Su
发明人： Reed L. Townsend , Mudit Agrawal , Andrey Borissov Batchvarov , Fei Su
IPC分类号： G06F3/048
CPC分类号： G06F3/04895 , G06F3/0481 , G06F3/04886
摘要： User experience of the performance of a computing device is improved through an operating system that processes inputs from a soft keyboard to provide information that can be used to accurately determine keys a user intended to strike while typing. For each detected tap, the operating system provides a probability that one or more keys were the intended target for the user. These probabilities may be computed from probability distribution functions that are dynamically determined based on user and/or system factors, such as typing rate and keyboard style or layout. Other components may use the probabilities to select a key corresponding to a detected keyboard tap as representing the intended user input. The selection may be made based on the probabilities alone or in combination with contextual factors that yield an overall probability that a detected tap arose from a user targeting a specific key.
摘要翻译：通过处理来自软键盘的输入的操作系统来提高计算设备的性能的用户体验，以提供可用于准确地确定打字时用户打算敲击的键的信息。对于每个检测到的抽头，操作系统提供一个或多个键是用户的预期目标的概率。这些概率可以根据基于用户和/或系统因素动态确定的概率分布函数来计算，诸如打字率和键盘风格或布局。其他组件可以使用概率来选择与检测到的键盘抽头对应的键来表示预期的用户输入。可以基于单独的概率或与产生检测到的抽头从针对特定键的用户产生的总体概率的上下文因素组合来进行选择。

7. 发明申请

US20120148533A1 COMBINATION THERAPY 有权
标题翻译：组合治疗
公开(公告)号：US20120148533A1
公开(公告)日：2012-06-14
申请号：US13313042
申请日：2011-12-07
申请人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
发明人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
IPC分类号： A61K38/21 , A61P35/00
CPC分类号： A61K38/212 , A61K31/437 , A61K38/21 , A61K2300/00
摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
摘要翻译：本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基-2,4-二氟 - 苯基] - 酰胺}或其药学上可接受的盐，以及用于治疗患有增殖性疾病，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的患者的干扰素。特别地，本发明涉及这样的治疗，其中干扰素是聚乙二醇化干扰素α-2a，该病症是含有V600E b-Raf突变的黑素瘤。

8. 发明申请

US20120045434A1 COMBINATION THERAPY 有权
标题翻译：组合治疗
公开(公告)号：US20120045434A1
公开(公告)日：2012-02-23
申请号：US13206557
申请日：2011-08-10
申请人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
发明人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
IPC分类号： A61K39/395 , A61P35/00 , A61K31/4738 , A61K31/437 , A61K31/517
CPC分类号： A61K31/4745 , A61K31/00 , A61K31/437 , A61K31/517 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
摘要翻译：本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基] 二氟 - 苯基} - 酰胺或其药学上可接受的盐，以及用于治疗患有增殖性病症的患者，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的EGFR抑制剂。

9. 发明授权

US09295669B2 Combination therapy for proliferative disorders 有权
标题翻译：联合治疗增生性疾病
公开(公告)号：US09295669B2
公开(公告)日：2016-03-29
申请号：US13313042
申请日：2011-12-07
申请人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
发明人： Kapil Dhingra , Brian Higgins , Kenneth Kolinsky , Richard J. Lee , Brian Lestini , Kathryn Packman , Fei Su
IPC分类号： A61K31/535 , A61K31/505 , A61K38/21 , A01N43/54 , A01N43/42 , C07D413/00 , C07D239/02 , C07D401/00 , C07D403/00 , C07D471/02 , A61K31/437
CPC分类号： A61K38/212 , A61K31/437 , A61K38/21 , A61K2300/00
摘要： The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.
摘要翻译：本发明涉及丙烷-1-磺酸{3- [5-（4-氯 - 苯基）-1H-吡咯并[2,3-b]吡啶-3-羰基-2,4-二氟 - 苯基] - 酰胺}或其药学上可接受的盐，以及用于治疗患有增殖性疾病，特别是实体瘤例如结肠直肠癌，黑素瘤和甲状腺癌的患者的干扰素。特别地，本发明涉及这样的治疗，其中干扰素是聚乙二醇化干扰素α-2a，该病症是含有V600E b-Raf突变的黑素瘤。

10. 发明授权

US08492127B2 Bacillus coagulans strains and their applications in L-lactic acid production 有权
标题翻译：凝结芽孢杆菌菌株及其在L-乳酸生产中的应用
公开(公告)号：US08492127B2
公开(公告)日：2013-07-23
申请号：US13698708
申请日：2010-11-22
申请人： Ping Xu , Limin Wang , Bo Zhao , Cuiqing Ma , Fei Su , Fei Tao , Hongzhi Tang
发明人： Ping Xu , Limin Wang , Bo Zhao , Cuiqing Ma , Fei Su , Fei Tao , Hongzhi Tang
IPC分类号： C12P7/56
CPC分类号： C12N15/75 , C12P7/56 , C12P2203/00 , C12R1/07
摘要： The invention is concerned with the strains of B. coagulans for lactic acid production and the related methods, in which the carbon sources are pentose or hexose or the agricultural or industrial wastes containing pentose or hexose or a mixture of both. According to the invention, the highest amount of L-lactic acid produced from glucose is 173 g/L, the optical purity is over 99%, the yield is up to 0.98, and the productivity is up to 2.4 g/L per hour. The highest amount of L-lactic acid produced from xylose is 195 g/L, the optical purity is over 99%, the yield is up to 0.98, and the productivity is up to 2.7 g/L per hour. The highest amount of L-lactic acid produced from reducing sugars in xylitol byproducts is 106 g/L, the optical purity is over 99%, and the productivity is up to 2.08 g/L per hour. The B. coagulans strains XZL4 (DSM No. 23183) and XZL9 (DSM No. 23184) of the invention can directly utilize various reducing sugars in xylitol byproducts to produce high amounts of L-lactic acid, which improves the production efficiency at low costs, and the strains are, thus, appropriate for industrial productions.
摘要翻译：本发明涉及用于乳酸生产的凝固芽孢杆菌菌株及其相关方法，其中碳源为戊糖或己糖，或者含有戊糖或己糖的农业或工业废物或两者的混合物。根据本发明，葡萄糖产生的L-乳酸量最高为173g / L，光学纯度超过99％，产率高达0.98，生产率高达2.4g / L。由木糖产生的L-乳酸含量最高为195g / L，光学纯度超过99％，产率高达0.98，生产率高达2.7g / L。由木糖醇副产物中的还原糖产生的最大量的L-乳酸为106g / L，光学纯度为99％以上，生产率高达每小时2.08g / L。本发明的凝结芽孢杆菌菌株XZL4（DSM No.23183）和XZL9（DSM No.23184）可以直接利用木糖醇副产物中的各种还原糖来生产大量的L-乳酸，以低成本提高生产效率，因此适用于工业生产。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式